🔗 Share this article

As the United States proceeds with sweeping changes to its immunization guidelines, one figure has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by questioning COVID-19 vaccines during the global health crisis and has zeroed in on potential fatalities after Covid vaccination in her brief time at the FDA.

Scheduled Shifts to Pediatric Vaccine Program

Health officials planned to unveil major changes to the pediatric immunization program recently, bringing the US with the Danish national calendar, it is understood – a significant shift that would place the US out of step with much of the international standard with little proof for benefit. The planned update has been pushed back until the new year.

In place of Vinay Prasad, Dr. Høeg is scheduled to speak at the event. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to head the center this year.

A Shift at the FDA

This interim role could signify a closer partnership between the drug and vaccine centers as Høeg and Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon rolling back long-standing vaccines at the FDA.

Høeg has repeatedly called for halting some childhood vaccine recommendations in the US so as to align more similar to the Danish model, a country with universal health coverage and a number of inhabitants approximately the size of Wisconsin’s.

In her initial statements, she has kept her attention on vaccination policy – traditionally the responsibility of Dr. Prasad, chief of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Background

Dr. Høeg has no apparent experience in drug development, regulation or leadership, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She is not versed in running a large organization. She lacks background in drug approvals.”

Previous directors of the center would “be deeply familiar with legal statutes and the science of drug development”, said a former acting FDA commissioner. “Frankly, she has not acquired the sort of resume that prior appointees who led CBER have had.”

CDER has an enormous range of responsibilities at the FDA, Woodcock pointed out.

“Many people just pays attention on the novel medication approvals, but the generic program approves a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and more, and each of these must be supervised,” Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

There is also, a substantial administrative component to the position, which supervises in excess of 5,000 personnel. “It’s a huge leadership role, if you execute it properly,” she said.

Agency Reaction and Contentious Policies

In response to inquiries about Dr. Høeg's qualifications and whether this appointment indicates more teamwork among agency officials on vaccines, a spokesperson stated that the “questions are based on inaccurate premises”.

“This background matches the functions of her position,” the spokesperson said, pointing to the time Høeg spent guiding the agency head on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg takes over the commissioner’s controversial priority voucher program, a contentious expedited drug-approval program that apparently concerned her predecessors. “By what process are these therapies being selected for this expedited pathway? Who takes the calls?” Dr. Howard asked. “There is a lot of lack of transparency happening at the agency right now.”

Overall, he stated, “the Food and Drug Administration appears to be shifting towards less stringent rules of all drugs, with the exception of shots.”

Established History on Immunizations

With immunizations, Høeg has a more established, if troubling, track record, some experts have noted. She published a study using non-validated volunteer-provided data to assess the rate of heart inflammation after Covid vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Included in her “wish list” for the current administration included altering guidelines for new vaccines and discontinuing “non-essential” immunizations, she stated following the vote on a podcast. At the FDA, Dr. Høeg has reportedly proposed barring teenage boys from receiving COVID-19 vaccines.

“She is an thorough dogmatist who starts off with her beliefs and reverse-engineers to retrofit the evidence in a extremely misleading, fraudulent fashion,” Howard said.

Taking Control and a “Revenge Tour”

Høeg became part of fellow dissenters, {like|